University of Colorado Hospital Selects CytoCare for IV Compounding
To Enhance Safety and Efficiency

Highland Beach, FL. (July 19, 2007) – Health Robotics recently announced that the University of Colorado Hospital (UCH) will become the first health care provider in North America to use its IV chemotherapy compounding robotic technology – CytoCare™. The robot will automate chemotherapy compounding for syringes and IV bags.

Health Robotics is the worldwide leader in patient specific, robotic chemotherapy admixtures. Its advanced technology and innovative engineering enhances sterility, delivers accurate doses for patients and helps protect clinicians from exposure to cytotoxic agents that can occur during manual compounding.

“We selected CytoCare to efficiently prepare the safest possible medications for our patients,” said Nancy Stolpman, PharmD, PhD, Director of Pharmacy at UCH. “CytoCare will be situated in our new Anschutz Inpatient Pavilion setting, it will initially be used to prepare products for our hospital patients and eventually we will add in the IV chemotherapy product needs for the University of Colorado Cancer Center as well. This new technology will significantly enhance the practice of pharmacy and will very likely become standard of care in the future.”

Strode Weaver, MHSA, MBA, Executive Director of Oncology Services at the University of Colorado Cancer Center, added: “Patient and staff safety is of the highest priority in working with chemotherapy agents. CytoCare is an important tool for us to optimize our compounding operations and deliver timely, accurate doses for every patient.”

More than 50 other CytoCare customers include activated sites at Charing Cross Hospital in London, University Hospital in Copenhagen and Campus Biomedico in Rome.

“We are very pleased to add UCH to our family of prestigious medical centers that utilize CytoCare for their chemotherapy compounding,” said Jack Risenhoover, senior partner with Health Robotics North America.

With its new Inpatient Pavilion at the Anschutz Medical Campus, UCH is using the most advanced technologies, including CytoCare, to treat cancer patients. UCH, an NCI designated facility, makes it easy for patients to access multidisciplinary clinical teams, including surgeons, oncologists, pathologists, radiologists, nurses, social workers, geneticists and counselors at one location and in one visit.

For more information on CytoCare, contact Primus Innovations at (972) 439-6821 or email us at primusinnovations@primusinnovations.com